Menu
Back to User profile » Dr Charlie Strange
Papers published by Dr Charlie Strange:
Long-Term SGRQ Stability in a Cohort of Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Choate R, Holm KE, Sandhaus RA, Mannino DM, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:889-900
Published Date: 10 April 2024
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2245-2256
Published Date: 12 October 2023
PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation
Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, Feigler N, Patel S, Pollack M
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:329-342
Published Date: 10 February 2022
Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD
Miller S, Teufel II R, Nichols M, Davenport P, Mueller M, Silverman E, Madisetti M, Pittman M, Kelechi T, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3263-3273
Published Date: 3 December 2021
Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
Sandhaus RA, Strange C, Zanichelli A, Skålvoll K, Koczulla AR, Stockley RA
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3313-3322
Published Date: 10 December 2020
Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3193-3199
Published Date: 3 December 2020
Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
Sandhaus R, Strange C, Stone G, Runken MC, Blanchette CM, Howden R
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2389-2397
Published Date: 5 October 2020
Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort
Trudo F, Kallenbach L, Vasey J, Chung Y, Wilk A, Slipski L, O'Brien D, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2625-2637
Published Date: 26 November 2019
Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life
Beiko T, Strange C
Therapeutics and Clinical Risk Management 2019, 15:959-964
Published Date: 31 July 2019
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
Strange C, Walker V, DePietro M, Tong J, Kurlander J, Carlyle M, Millette LA, Wittbrodt E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1377-1388
Published Date: 28 June 2019
Oropharyngeal swallow physiology and swallowing-related quality of life in underweight patients with concomitant advanced chronic obstructive pulmonary disease
Garand KL, Strange C, Paoletti L, Hopkins-Rossabi T, Martin-Harris B
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2663-2671
Published Date: 29 August 2018
Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
Tashkin DP, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2587-2601
Published Date: 27 August 2018
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
Lal C, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:135-140
Published Date: 30 December 2016
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2055-2066
Published Date: 28 September 2015
Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population
Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1417-1425
Published Date: 23 July 2015
Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history
Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1409-1416
Published Date: 21 July 2015